尼酸盐对冠状动脉疾病患者在不同左心室喷射小部分的作用
Hui Liu1, Wei Liu1, Yalin Cao1
1Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Frontiers in cardiovascular medicine
|March 9, 2026
概括
长效酸盐通常用于冠状动脉疾病 (CAD). 在左心室喷射分数减少的患者中 (LVEF <45%),酸盐与更糟糕的长期结果有关,包括死亡和主要心血管不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 长效酸盐经常被用于冠状动脉疾病 (CAD).
- 在CAD患者中,酸盐使用与长期结果之间的关联受到辩论.
- 左心室喷射分数 (LVEF) 对这种关联的修饰作用尚不清楚.
研究的目的:
- 调查排放酸盐处方与CAD患者的长期结果之间的关联.
- 确定LVEF是否会改变酸盐使用与CAD结果之间的关系.
主要方法:
- 对2,404名接受冠状动脉血管造影的成人CAD患者进行了回顾性队列研究.
- 根据LVEF (<45%,45%-55%,>55%) 和出院时的酸盐处方分层的患者.
- 主要终点:全因死亡. 二级终点:主要心血管不良事件 (MACE).
- 使用了卡普兰-梅尔和多变量考克斯回归分析.
主要成果:
- 排放时酸盐的使用与所有原因的死亡或MACE在整体队列中没有关联.
- 在LVEF<45%的患者中,酸盐使用与所有原因死亡 (HR 2.14) 和MACE (HR 1.91) 的风险显著增加.
- 在45%-55%或>55%的LVEF患者中没有观察到显著的关联.
结论:
- 在CAD患者中,出院时的酸盐处方是常见的.
- 酸盐与长期结果之间的不良关联仅在LVEF降低 (<45%) 的患者中观察到.
- 建议在减少LVEF的CAD患者中谨慎使用酸盐,需要进一步的前性研究.
相关概念视频
Antianginal Drugs: Nitrates and β-Blockers
1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Heart Failure V: Medical Management
453
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453
Angina V: Nursing Management
457
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
457
Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K


